Donald Trump signed an executive order directing the FDA to accelerate clinical trials and research for psychedelic drugs to treat mental health conditions in veterans.The policy prioritizes ibogaine and other substances for PTSD and addiction, supported by 50 million dollars in federal funding and expedited rescheduling pathways.HHS officials and health experts confirmed that this initiative represents a major shift toward integrating psychedelic medicine into the US healthcare system.